首页> 外国专利> METHOD FOR TREATING ISCHEMIC CARDIAC DISEASE, OR MYOCARDIAL INFARCTION AND ITS AFTEREFFECTS, OR CEREBRAL ISCHEMIA INDUCED BY ATHEROSCLEROSIS OR ACUTE DYSFUNCTION OF CEREBRAL CIRCULATION, AND ITS AFTEREFFECTS, OR ATHEROSCLEROSIS-INDUCED ISCHEMIA OF INFERIOR LIMBS

METHOD FOR TREATING ISCHEMIC CARDIAC DISEASE, OR MYOCARDIAL INFARCTION AND ITS AFTEREFFECTS, OR CEREBRAL ISCHEMIA INDUCED BY ATHEROSCLEROSIS OR ACUTE DYSFUNCTION OF CEREBRAL CIRCULATION, AND ITS AFTEREFFECTS, OR ATHEROSCLEROSIS-INDUCED ISCHEMIA OF INFERIOR LIMBS

机译:治疗缺血性心脏病,心肌梗塞及其影响或因动脉粥样硬化或急性脑循环功能障碍引起的脑缺血及其影响,或因粥样硬化引起的缺血性缺血的方法

摘要

FIELD: medicine.;SUBSTANCE: the present innovation deals with treating diseases associated with affected tissue circulation. It deals with injecting mononuclear cells of donor's umbilical cord blood into the blood. Moreover, the above-mentioned donor's cells have got the set of antigens HLA-A, HLA-B, HLA-DR being distinct against the recipient's set of antigens HLA-A, HLA-B, HLA-DR by not less than four antigens. The quantity of introduced cells ranges 2.5 x 106 up to 10 x 106/kg body weight/d. Injection should be repeated 2-10 times at interval of 10-60 d. The innovation provides substitution of dead and/or recipient's regeneration-impotent cells with the above-mentioned donor's cells and enables to decrease the frequency of immunopathological reactions at decreasing the number of introduced donor's mononuclear cells.;EFFECT: higher efficiency of therapy.;2 cl, 8 ex, 1 tbl
机译:领域:医学。;物质:本发明涉及与受影响的组织循环相关的疾病的治疗。它涉及将供体脐带血的单核细胞注入血液中。此外,上述供体细胞获得的抗原HLA-A,HLA-B,HLA-DR的集合与接受者的抗原HLA-A,HLA-B,HLA-DR的集合具有至少四个抗原的区别。引入的细胞数量范围为2.5 x 10 6 / kg体重/ d至10 x 10 6 / kg体重/ d。注射应以10-60 d的间隔重复2-10次。这项创新技术可以用上述供体细胞替代死细胞和/或受体的再生异能细胞,并通过减少供体单核细胞的数量来降低免疫病理反应的频率。效果:更高的治疗效率; 2 cl,8 ex,1 tbl

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号